91 related articles for article (PubMed ID: 1992325)
1. Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation.
N Engl J Med; 1991 Feb; 324(9):631-3. PubMed ID: 1992325
[No Abstract] [Full Text] [Related]
2. [Immunoglobulin therapy in patients after autologous and allogeneic bone marrow transplantation].
Körholz D; Grünewald S; Burdach S; Göbel U
Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():68-71; discussion 72. PubMed ID: 8499754
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporin A: use in preventing graft versus host disease.
Klemm P
Oncol Nurs Forum; 1985; 12(5):25-32. PubMed ID: 3898028
[No Abstract] [Full Text] [Related]
4. UVB irradiated allogeneic bone marrow transplantation in rats: prevention of graft versus host disease without immunosuppression.
Pepino P; Hardy MA; Chabot JA; Berger C; Marboe C; Wasfie T
Transplant Proc; 1989 Feb; 21(1 Pt 3):2995-6. PubMed ID: 2523168
[No Abstract] [Full Text] [Related]
5. The prevention of oral complications in bone-marrow transplantations by means of oral hygiene and dental intervention.
Raber-Durlacher JE; Abraham-Inpijn L; van Leeuwen EF; Lustig KH; van Winkelhoff AJ
Neth J Med; 1989 Feb; 34(1-2):98-108. PubMed ID: 2644559
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression, graft-versus-host disease, and infection after bone marrow transplantation.
Kramer BS; Elfenbein GJ
J Fla Med Assoc; 1984 May; 71(5):321-8. PubMed ID: 6429272
[No Abstract] [Full Text] [Related]
7. Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation.
Spitzer TR; Cottler-Fox M; Sullivan P; Lynch M; Tefft MC; Pickle LW; Cirenza E; Cahill R; Deeg HJ; Sacher R
Semin Hematol; 1992 Jul; 29(3 Suppl 2):123-6. PubMed ID: 1509292
[No Abstract] [Full Text] [Related]
8. Experience with sandoglobulin in bone marrow transplantation.
Tutschka PJ; Copelan EA
Int J Cell Cloning; 1986; 4 Suppl 1():181-8. PubMed ID: 3018102
[No Abstract] [Full Text] [Related]
9. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
10. Complement and humoral immune parameters in bone marrow transplant recipients: effects of intravenous immunoglobulin administration.
Späth PJ; Baumgartner C; Gratwohl A; Doran JE; Elisa A; Bachmann P; Scherz R; Berger C; Morell A; Tichelli A
Transplant Proc; 1989 Feb; 21(1 Pt 3):3064-6. PubMed ID: 2495696
[No Abstract] [Full Text] [Related]
11. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation.
Champlin R
Hematol Oncol Clin North Am; 1990 Jun; 4(3):687-98. PubMed ID: 2193019
[TBL] [Abstract][Full Text] [Related]
12. Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation.
Champlin R; Gajewski J; Feig S; Giorgi J; Lyddane N; Lee K; Schmidt I; Winston D; Ho W; Reichert T
Transplant Proc; 1989 Feb; 21(1 Pt 3):2947-8. PubMed ID: 2495694
[No Abstract] [Full Text] [Related]
13. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
Gluckman E; Devergie A; Lokiec F
Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
[No Abstract] [Full Text] [Related]
14. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
[TBL] [Abstract][Full Text] [Related]
15. Etanercept in graft-versus-host disease.
Andolina M; Rabusin M; Maximova N; Di Leo G
Bone Marrow Transplant; 2000 Oct; 26(8):929. PubMed ID: 11081399
[No Abstract] [Full Text] [Related]
16. [Prevention and treatment of various infections after bone marrow transplantation].
Moriyama Y
Nihon Rinsho; 1990 Sep; 48(9):2028-34. PubMed ID: 2232207
[No Abstract] [Full Text] [Related]
17. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
18. [Prognosis and course of bone marrow transplantation].
Ostendorf P
Verh Dtsch Ges Inn Med; 1986; 92():431-4. PubMed ID: 3544568
[No Abstract] [Full Text] [Related]
19. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
[TBL] [Abstract][Full Text] [Related]
20. Combination prophylactic immunosuppression in bone marrow transplantation.
Szer J
Transplant Proc; 1989 Feb; 21(1 Pt 3):3011-2. PubMed ID: 2650415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
